Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,501 - 1,550 out of 6,656

Document Document Title
WO1999012944A3
The present invention is directed to novel compositions and their use in the treatment of inflammatory responses. Specifically, the invention is directed to novel synthetic oligosaccharide constructs and their use to block lymphocyte bin...  
WO/1999/041275A1
A pharmaceutical compound or an intermediate therefor, having the formula: D*-Linker*(R¿2?')¿k?-R¿2?, where R¿2? and R¿2?' (if present) is the amide or ester residue of an aliphatic amino acid, k is 0 or 1, D* is a Drug residue bear...  
WO/1999/041268A1
Compounds of formula (I) wherein R is independently H or -CH¿3? and pharmaceutically acceptable salts thereof have favourable pharmacological properties and are antivirally active against HBV and HIV.  
WO/1999/040097A1
Clarithromycin is prepared from erythromycin A 9-alkylidenehydrazones, erythromycin A 9-alkyl- and arylsulfonylhydrazones, erythromycin A 9-N-alkylhydrazones or erythromycin A 9-N,N-dialkylhydrazones.  
WO/1999/039719A1
Preventives and remedies for ischemic reflow disorder containing chromanol glycosides represented by general formula (1) as the active ingredient: wherein R?1¿, R?2¿, R?3¿ and R?4¿ are the same or different and each represents hydrog...  
WO/1999/038858A1
To provide an external agent for the skin that not only exhibits excellent effects of prevention and amelioration of skin pigmentation but also has no fear of giving adverse influences to the skin and can be used safely, there is added t...  
WO/1999/038876A1
Glycosidation of 4,5-Epoxymorphinan-6-ols with a Thioglycoside as a glycoside donor is disclosed. The process comprises reacting a 4,5-Epoxymorphinan-6-ol and a Thioglycoside in the presence of a thiophilic promoter under conditions capa...  
WO1999022722A3
A method for treating tumors and macular degeneration in a human or veterinary patient comprising administering a compound selected from the group consisting of (I), (II), (III), (IV), (V), (VI), (VII), and a pharmaceutical composition c...  
WO/1999/038877A2
There are provided according to the invention, novel compounds of formula (I) wherein R?1¿, R?2¿ and R?3¿ are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for t...  
WO1999002162A9
A range is disclosed of purine derivatives (I) which can act as inhibitors of cyclin dependent kinases (CDKs) and which thereby c an provide useful therapeutic compounds for use in treatment of tumours or other cell proliferation disorde...  
WO/1999/037310A1
Methods of providing pain relief which include the steps of identifying an animal in need of pain relief and administering an amount of a compound of Formula (II) sufficient to provide pain relief.  
WO/1999/035156A1
The invention relates to novel erythromycin analogs and azalides, particularly ones with novel C-13 substituents, and to pharmaceutically acceptable salts thereof. The compounds of this invention are antibacterial agents that may be used...  
WO/1999/035157A1
The invention relates to novel erythromycin derivatives, particularly ones with novel C-13 R?13¿ substituents, and to pharmaceutically acceptable salts thereof. The compounds of this invention are useful as antibacterial agents and anti...  
WO/1999/035155A1
The invention concerns compounds of formula (I), in which Y is oxygen, N-Nalc¿1? or NOalc¿2?; X represents hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, CONOR or NRcRd, Rc and Rd being hydrogen or alkyl; Z represents hydrogen, h...  
WO/1999/035138A1
A process for the preparation of isoflavone compounds which comprises separating an isoflavone compound from a raw material containing the isoflavone compound and/or precursors thereof through extraction, characterized in that the raw ma...  
WO1999020639A3
The invention relates to compounds of general formula (I) characterized in that R<1> individually stands for hydroxyl, L-cladinosyl group of formula (II) wherein R<2> individually stands for hydrogen or a silyl group; R<3> individually s...  
WO/1999/032499A1
A 4'-O-demethyl-epipodophyllotoxin-$g(b)-D-glucoside acetal derivative of formula (I), wherein R?1¿ and R?2¿ are, each independently, hydrogen, a C¿2-12? alkenyl, a C¿2-12? alkynyl, C¿2-12? alkoxylalkyl or cyclopropyl group optional...  
WO/1999/032500A2
Erythromycin A oxime wherein the hydroxyl group of the oxime group is in reacted form resulting from reaction with a strong organic base or with a silylation agent; a process for its production and its use as an intermediate in the produ...  
WO/1999/031114A1
The claimed invention provides a novel method of preparing 6-O-methyl erythromycin A. The process comprises the steps of reducing the 9-keto group of erythromycin A to form a 9-hydroxy erythromycin A, protecting the 9-, 2'-, and/or 4'-hy...  
WO/1999/029709A1
Novel erythromycin derivatives represented by general formula (I) and drugs containing these derivatives as the active ingredient and being useful in treating atypical acid-fast bacterium infection, wherein R?1¿ represents hydrogen or l...  
WO/1999/029704A1
This invention provides a process for the preparation of a Eleutherobin derivative of formula wherein R¿1? is a hydrogen, ester, nitrile or CH¿2?-R¿4? (I), wherein R¿4? is a carbohydrate, an alcohol, an amine, an amide, an alkyne; or...  
WO/1999/028333A1
A process of preparing a 6-O-alkyl derivative of erythromycin C is provided. The process includes the steps of protecting the 2',4'- and 9-oxime hydroxyls with acetyl and ketal protecting groups, alkylating the 6-hydroxyl, removing the p...  
WO/1999/028308A1
A group of reagents, as diisocyanates, dianhydrides, diacidchlorides, diepoxides, carbodiimides and the like are utilized to link a wide variety of antibiotic moieties, reacted two at a time with said reagents, the said antibiotic moieti...  
WO/1999/027943A1
The invention concerns the use of ginkgo biloba extracts for preparing a medicine for facilitating the withdrawal of individuals dependent on the consumption of a substance generating dependence and/or addiction, such as alcohol, ampheta...  
WO/1999/028332A1
A process of preparing a 6-O-alkyl derivative of 9-oxime erythromycin B is provided. Intermediates used in the preparation of a 6-O-alkyl 9-oxime erythromycin B are also provided. Pharmaceutical compositions containing a 6-O-alkyl deriva...  
WO/1999/025365A1
The invention concerns a novel therapeutic application of ketolides for preparing pharmaceutical compositions for preventing arterial thrombotic complications related to atherosclerosis.  
WO/1999/025723A1
A process of preparing 6-O-alkyl erythromycin A is provided. The process includes the steps of protecting the oxime hydroxyl of 9-oxime erythromycin A with a benzoyl protecting group, protecting the 2'-hydroxyl group and optionally the 4...  
WO/1999/025722A1
Disclosed is an improved and efficient process for N-desmethylating the 3'-amino nitrogen of erythromycins and for converting the 3'-N-desmethylated erythromycins into 3'-N-substituted derivatives of 8,9-anhydro-erythromycin 6,9-hemiketals.  
WO/1999/022722A2
A method for treating tumors and macular degeneration in a human or veterinary patient comprising administering a compound selected from the group consisting of (I), (II), (III), (IV), (V), (VI), (VII), and a pharmaceutical composition c...  
WO/1999/021550A1
A compound of Formula (1) wherein R?1¿ and R?2¿ are independently H, OH, halogen, CF¿3?, a glucopyranosyloxy group or an optionally substituted C¿1-6? straight or branched chain alkyl group, C¿1-6? alkoxy group, aryl C¿2-6? alkenyl...  
WO/1999/021867A1
Erythromycin A derivatives represented by general formula (I) or pharmaceutically acceptable salts thereof.  
WO/1999/021865A1
The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts thereof, wherein R?1¿, R?2¿, R?3¿, R?4¿ and R?5¿ are as defined herein. The invention also relates to pharmaceutical compositions containing ...  
WO/1999/021871A1
Novel 2-halo-6-O-substituted ketolide derivatives and pharmaceutically acceptable salts and esters thereof having antibacterial activity having formula (I) or (II), compositions comprising a therapeutically effective amount of a compound...  
WO/1999/021869A1
An erythromycin A derivative represented by formula (I) wherein n is an integer of 1 to 7, R?1¿ is a group represented by the formula: -SO¿2?N(-R?7¿)-R?8¿ or N-(R?10¿)SO¿2?R?9¿, R?2¿ is a hydrogen atom, an alkyl group or a cinnam...  
WO/1999/021864A1
Novel 6,11-bridged erythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity having formula (I) or (II); compositions comprising a therapeutically effective amount of a compound of the ...  
WO/1999/021870A1
An erythromycin A derivative represented by formula (I), wherein n is an integer of 1 to 7, R?1¿ is a hydrogen atom or an alkyl group, R?2¿ is a quinolyl group, a pyrazinyl group, a benzimidazolyl group, a thiazolyl group, a pyridyl gr...  
WO/1999/021866A1
The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts thereof, wherein R?1¿, R?2¿, R?3¿, R?4¿ and X are as defined herein. The invention also relates to pharmaceutical compositions containing the ...  
WO1999011651A3
Novel multicyclic erythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity having a formula selected from the group consisting of (I), (II), (III), (IV) and (V), compositions comprisin...  
WO/1999/021868A1
Erythromycin A derivatives represented by general formula (I) or pharmaceutically acceptable salts thereof: wherein n represents an integer of 1 to 8; R?1¿ represents hydrogen or C¿1?-C¿6? alkyl; R?2¿ represents pyridylmethyl, quinol...  
WO/1999/020639A2
The invention relates to compounds of general formula (I) characterized in that R?1¿ individually stands for hydroxyl, L-cladinosyl group of formula (II) wherein R?2¿ individually stands for hydrogen or a silyl group; R?3¿ individuall...  
WO/1999/020261A2
The invention involves methods and materials for treating and preventing non-invasive fungus-induced mucositis. Specifically, the invention involves administrating an antifungal agent such that it contacts mucus in an amount, at a freque...  
WO/1999/020791A1
Methods for treating and preventing the onset and maintainance of multiple drug resistance (MDR) in animals undergoing chemotherapy for cancer are provided wherein target cells are depleted of adenosine 5'-monophosphate (AMP) and adenosi...  
WO/1999/019331A1
Compounds are disclosed which are represented by formula (I) as well as salts and hydrates thereof wherein in part: X represents CH¿2?, CHF, CF¿2?, C=CH¿2?, CHSR, CHCH¿3?, C=S, C=O or CHOR. Pharmaceutical compositions and methods of ...  
WO/1999/019319A1
A process is disclosed for the production of polyphenol oligomers having n polyphenol monomeric units, n being an integer from 2-18. The process includes coupling of a protected polyphenol, having protected phenolic hydroxyl groups, whic...  
WO/1999/018109A1
A process of preparing ring E-modified analogues of (-)-podophyllotoxin as potential new chemotherapeutic agents. The process generates corresponding analogues of (-)-podophyllotoxin, itself, aand allows new molecular interactions in the...  
WO1998054308A3
The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) pro...  
WO/1999/016778A1
Disclosed are the antibacterial compounds having formulas (I) or (II) or pharmaceutically acceptable salts and esters thereof. Also disclosed are the processes for preparing compounds of formulas (I), and (II) of the invention, pharmaceu...  
WO/1999/016779A1
Novel 3'-N-modified 6-O-substituted erythromycin ketolide compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity having formula (I), (II), (III), (IV) or (V), compositions comprising a therapeuti...  
WO1999003986A3
Modified PKS gene clusters which produce novel polyketides in an efficient system in a host cell or in a cell free extract are described. The novel polyketides result from the incorporation of diketides of formula (1) or (2), wherein A i...  
WO1999002541A3
Erythromycin A oxime; in anhydrous and stable form; in the form of a solvate with non-halogenated organic solvent; and in the form of a hemihydrate, processes for its productions; and their use in the production of a semi-synthetic macro...  

Matches 1,501 - 1,550 out of 6,656